Company intelligence
Global Antibiotic R&D Partnership (GARDP)
Putting public health needs at the centre of antibiotic drug development to address the crisis of AMR
About Global Antibiotic R&D Partnership (GARDP)
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org
Verified activity
Signals from Global Antibiotic R&D Partnership (GARDP)
3 published signals
Presence & Recognition
Global Antibiotic R&D Partnership (GARDP) is participating in a WorldSepsisDay webinar discussing neonatal antimicrobial stewardship and antibiotic use for newborns.
Reported by Global Antibiotic R&D Partnership (GARDP)
Research & Knowledge
Global Antibiotic R&D Partnership (GARDP) published new findings from the PediCAP trial published in The Lancet Group suggesting that for many young children, the answer is no, once a child has received at least 24 hours of antibiotics through a vein, improved clinically, and can take medicines by mouth, they can safely switch to oral amoxicillin or co-amoxiclav.
Reported by Global Antibiotic R&D Partnership (GARDP)
Presence & Recognition
Global Antibiotic R&D Partnership (GARDP) is hosting the Antimicrobial Chemotherapy Conference 2027 on 9–11 February 2027 at the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) framework.
Reported by Global Antibiotic R&D Partnership (GARDP)